Tarsus Pharmaceuticals (TARS) Stock Chart & Stock Price History $41.40 +0.82 (+2.02%) As of 01:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Tarsus Pharmaceuticals Stock Price Performance The Tarsus Pharmaceuticals (TARS) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 45.41%, with a year-to-date return of -25.23%. In the past month, the stock has increased 0.26%, reflecting recent market activity. As of the latest close, Tarsus Pharmaceuticals traded at $40.58 with a market cap of $1.70 billion and volume of 538,928 shares. Receive TARS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+5.66%1 Month Performance+0.26%3 Month Performance-16.18%Year-To-Date Performance-25.23%1 Year Performance+45.41% TARS Stock Chart for Wednesday, July, 16, 2025 TARS Chart by TradingView Tarsus Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/15/2025$41.53$40.58-2.29%$41.58$40.14538,928 shs$1.70 billion07/14/2025$39.18$41.53+6.00%$41.70$39.50561,914 shs$1.74 billion07/11/2025$41.16$39.18-4.81%$41.01$39.11647,499 shs$1.65 billion07/10/2025$41.29$41.16-0.31%$41.72$40.69540,823 shs$1.73 billion07/09/2025$39.69$41.29+4.03%$41.40$39.54613,835 shs$1.73 billion07/08/2025$39.93$39.69-0.60%$40.42$38.52557,710 shs$1.67 billion07/07/2025$41.08$39.93-2.80%$40.98$39.75486,432 shs$1.68 billion07/04/2025$41.08$41.08$41.48$40.04274,097 shs$1.73 billion07/03/2025$40.45$41.08+1.56%$41.48$40.04274,097 shs$1.70 billion07/02/2025$39.99$40.45+1.15%$41.06$39.40413,304 shs$1.70 billion Get the Latest News and Ratings for TARS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/01/2025$40.51$39.99-1.28%$41.03$39.191.06 million shs$1.68 billion06/30/2025$40.35$40.51+0.40%$41.50$40.38444,832 shs$1.70 billion06/27/2025$40.33$40.35+0.05%$41.10$39.80951,826 shs$1.70 billion06/26/2025$40.20$40.33+0.32%$40.72$39.50367,312 shs$1.69 billion06/25/2025$41.40$40.20-2.90%$42.00$40.03374,768 shs$1.69 billion06/24/2025$40.60$41.40+1.97%$41.86$40.40399,142 shs$1.74 billion06/23/2025$40.65$40.60-0.12%$41.54$40.29718,075 shs$1.71 billion06/20/2025$41.07$40.65-1.02%$41.30$39.331.28 million shs$1.71 billion06/19/2025$41.07$41.07$41.09$39.34783,226 shs$1.73 billion06/18/2025$39.42$41.07+4.19%$41.09$39.34783,226 shs$1.73 billion06/17/2025$41.29$39.42-4.53%$41.16$39.25616,698 shs$1.66 billion06/16/2025$40.89$41.29+0.98%$42.01$40.90572,860 shs$1.73 billion Related Companies Legend Biotech Stock Price Chart Grifols Stock Price Chart TG Therapeutics Stock Price Chart Nuvalent Stock Price Chart Lantheus Stock Price Chart Telix Pharmaceuticals Stock Price Chart Axsome Therapeutics Stock Price Chart CRISPR Therapeutics Stock Price Chart ADMA Biologics Stock Price Chart Vaxcyte Stock Price Chart Receive TARS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:TARS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
